Idiopathic pulmonary fibrosis (IPF) is the most prevalent of the idiopathic interstitial
pneumonias and its incidence seems to be increasing [1–4]. IPF is generally considered to …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia
of unknown cause that is limited to the lungs [1]. The disease is inevitably fatal, with an …

Idiopathic pulmonary fibrosis (IPF) is a parenchymal lung disease characterized by
progressive interstitial fibrosis. The clinical course of IPF can be unpredictable and may be …

Idiopathic pulmonary fibrosis (IPF) is a devastating disease, with a median survival from
diagnosis of only 3 years [1]. Although it is a rare and somewhat orphan disease [2], its …

In idiopathic pulmonary fibrosis (IPF), some facts or concepts based on substantial evidence,
whilst implicit for learned subspecialists, have previously been neglected and/or not …

Idiopathic pulmonary fibrosis (IPF) is an important, and devastating, interstitial lung disease.
It has a median mortality of only 3 years, worse than many cancers, and its incidence …

Idiopathic pulmonary fibrosis (IPF) is a specific type of fibrosing interstitial pneumonia of
unknown cause. It is usually chronic and progressive, tends to affect mainly adults over age …

In 2011, revised international guidelines were issued jointly by the American Thoracic
Society, the European Respiratory Society, the Japanese Respiratory Society and the Latin …

Idiopathic pulmonary fibrosis (IPF) is a steadily progressive and ultimately fatal disease of
unknown origin. Recent years have seen advances in our understanding of IPF and a …

Background Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the
European Medicines Agency and the US Food and Drug Administration for the treatment of …